Author

Andrew J. Powell

GlaxoSmithKline (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Aurora Irene IdilliiD· 1 shared Benjamin J. Mortishire-SmithiD· 1 shared Cesira de ChiaraiD· 1 shared David HouseiD· 1 shared Elliot FellowsiD· 1 shared Emma E. CawoodiD· 1 shared Federica RaguseoiD· 1 shared Fernanda Teixeira SubtiliD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

Aurora Irene IdilliORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Phenotype-first covalent fragment screening identifies a synthetic lethal TYMS inhibitor in ATRX-deficient cells

Federica Raguseo, Elliot Fellows, Cesira de Chiara, Benjamin J. Mortishire-Smith, Sandra Segura‐Bayona, Emma E. Cawood, Ming Jiang, Fernanda Teixeira Subtil, Aurora Irene Idilli, William J. McCarthy, Michael Howell, Katrin Rittinger, James I. MacRae, Mark J. Skehel, Andrew J. Powell, , Simon J. Boulton

The paper identifies a covalent fragment inhibitor of TYMS that selectively kills ATRX-deficient cells through replication stress.

bioRxiv · Jun 11, 2026 · PreprintCell Biology